Oruka Therapeutics (ORKA) net assets (shareholders' equity)

Net assets · fiscal 2025
$471.93M

Oruka Therapeutics (ORKA) had net assets of $471.93M at the end of fiscal 2025 (December 31, 2025). That is 23.5% higher than the $382.22M of fiscal 2024. Figures as of 19 Nov 2026, 00:22 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Net assets, fiscal 2025
$471.93M
Change on fiscal 2024
+23.5%
Growth, 5 years
+58.9% a year
Growth, 10 years
+28.6% a year
Highest on record
$471.93Mfiscal 2025
Lowest on record
-$38.18Mfiscal 2008
Fiscal years on record
222004–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Oruka Therapeutics net assets (shareholders' equity), in more detail

Over the five fiscal years to 2025 net assets grew at a compound 58.9% a year; over ten years the rate was 28.6% a year. Across the 22 fiscal years on record (2004–2025), the highest was $471.93M in fiscal 2025 and the lowest -$38.18M in fiscal 2008.

History · 22 fiscal years

Net assets by fiscal year

Oruka Therapeutics net assets (shareholders' equity), year by year

Oruka Therapeutics (ORKA) net assets (shareholders' equity) by fiscal year
Fiscal yearNet assetsChangeYear ended
2025$471.93M 23.5% up
2024$382.22M 932.5% up
2023$37.02M 11.2% down
2022$41.67M 18.4% down
2021$51.04M 9.7% up
2020$46.52M 511.3% up
2019$7.61M 26.2% up
2018$6.03M 41.3% down
2017$10.28M 53.7% down
2016$22.19M 41.7% down
2015$38.07M 158.3% up
2014$14.74M 5.4% down
2013$15.58M 436.0% up
2012$2.91M 49.3% down
2011$5.73M 15.3% down
2010$6.77M 8.6% down
2009$7.41M—
2008-$38.18M—
2007-$19.69M—
2006-$5.74M—
2005-$678.00K—
2004-$619.00K—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.

How to read it

Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.

Net assets at health care companies of similar size

Net assets of Oruka Therapeutics and comparable companies
CompanyNet assetsFiscal year
Immunovant IMVT$852.59M2026
Axsome Therapeutics AXSM$88.30M2025
Chemed CHE$979.41M2025
Oruka Therapeutics ORKA$471.93M2025
Arrowhead Pharmaceuticals ARWR$50.31M2026
MSA Safety MSA$1.37B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on ORKA

Oruka Therapeutics, figure by figure

Oruka Therapeutics (ORKA) overview: price, valuation and scorecardAll health care companies by market value

Oruka Therapeutics net assets (shareholders' equity): questions and answers

What are Oruka Therapeutics's net assets?

Oruka Therapeutics (ORKA) had net assets of $471.93M at the end of fiscal 2025 (December 31, 2025). That is 23.5% higher than the $382.22M of fiscal 2024.

What is the growth rate of Oruka Therapeutics's net assets?

Over the five fiscal years to 2025 net assets grew at a compound 58.9% a year; over ten years the rate was 28.6% a year.

What are the highest and lowest net assets figures on record for Oruka Therapeutics?

Across the 22 fiscal years on record (2004–2025), the highest was $471.93M in fiscal 2025 and the lowest -$38.18M in fiscal 2008.

How is Oruka Therapeutics's net assets calculated?

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Oruka Therapeutics it is on record here for 22 fiscal years, 2004 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Oruka Therapeutics (ORKA) net assets (shareholders' equity)”, data as of 19 November 2026. https://funkfolio.com/stock/ORKA/net-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.